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Erratum
The chemopotentiation of cisplatin by the novel bioreductive
drug AQ4N
R Gallagher, CM Hughes, MM Murray, OP Friery, LH Patterson, DG Hirst and SR McKeown*
British Journal of Cancer (2002) 87, 1339. doi:10.1038/sj.bjc.6600561 www.bjcancer.com
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Correction to: British Journal of Cancer (2001) 84, 625–929.
doi:10.1054/sj.bjc.2001.1975
Unfortunately due to an error Figure 5 was reproduced incorrectly.
The correct version is printed below.
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Figure 5 The effect of AQ4N and TPZ on the bone marrow toxicity of
cDDP. BDF mice were dosed i.p. with AQ4N (100 mg/kg) 30 min or 6 h
prior to cDDP (4 or 8 mg/kg). TPZ (25 mg/kg) was administered 2.5 h
prior to cDDP (4 or 8 mg/kg). The survival of bone marrow cells was as-
sessed by the spleen colony assay. Results are means+S.E. for six mice.
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